SECOND AMENDMENT TO THE COLLABORATION AGREEMENTCollaboration Agreement • February 24th, 2010 • Facet Biotech Corp • Pharmaceutical preparations
This SECOND AMENDMENT TO THE COLLABORATION AGREEMENT (this "Second Amendment"), effective January 20, 2010 (the "Second Amendment Effective Date"), is made and entered into by and between FACET BIOTECH CORPORATION, a Delaware corporation having its principal place of business at 1500 Seaport Blvd., Redwood City, California 94063 ("Facet" or "PDL"), and BIOGEN IDEC MA INC., a Massachusetts corporation having its principal place of business at 14 Cambridge Center, Cambridge, Massachusetts 02142 ("Biogen Idec"). Facet and Biogen Idec are sometimes referred to herein individually as a "Party" and collectively as the "Parties".
CONFIDENTIAL PROVISIONS REDACTED Amendment No. 2 to Asset Purchase AgreementAsset Purchase Agreement • February 24th, 2010 • Facet Biotech Corp • Pharmaceutical preparations
This Amendment No. 2 to Asset Purchase Agreement (this "Amendment"), effective as of October 19, 2009 (the "Amendment Effective Date"), is made by and between Facet Biotech Corporation, a Delaware corporation ("Facet"), and EKR Therapeutics, Inc., a Delaware corporation ("EKR"). Unless otherwise defined in this Amendment, capitalized terms used in this Amendment shall have the meanings assigned thereto in the Asset Purchase Agreement, effective February 4, 2008, between Facet (as successor in interest to PDL BioPharma, Inc. thereunder) and EKR, as amended March 7, 2008 (as amended, the "Agreement").
